How Psychedelics Got Stuck At Schedule I

The Controlled Substances Act of 1970 created a five-tier scheduling system managed jointly by the Drug Enforcement and Food and Drug Administration. Schedule I is the most restrictive tier, reserved for substances deemed to have no medical use and a high potential for abuse. Placement there makes a drug both illegal and nearly impossible to study. Researchers must obtain a special DEA license, secure an FDA Investigational New Drug application and navigate a years-long institutional approval process before enrolling a single patient.

Ibogaine was placed on Schedule I in 1970. So were psilocybin, LSD and MDMA. Those decisions were made in the context of the Nixon administration’s war on drugs with minimal scientific input. The result was a 50-plus-year research freeze that left clinicians with almost no rigorous data on whether these substances could safely treat anything, even as anecdotal reports and small studies suggested they might.

What The Science Of Psychedelics Actually Shows

Ibogaine binds to multiple receptor systems in the brain simultaneously producing a prolonged psychedelic experience that can last 24 to 36 hours. Researchers believe this neurochemical disruption may allow the brain to reset deeply entrenched patterns of fear, addiction and trauma in ways that conventional medications can’t.

The evidence base for psychedelic-assisted therapies has expanded meaningfully in the last decade but remains thin by FDA standards.

The safety concerns surrounding ibogaine are very real. The drug can trigger dangerous cardiac arrhythmias and has been linked to 27 to 30 deaths in the medical literature. The NIH briefly funded pre-clinical ibogaine research in the 1990s but chose not to fund human trials specifically due to heart toxicity.

A 2024 Stanford study of 30 veterans who received ibogaine paired with intravenous magnesium to protect their heart rhythm found significant reductions in PTSD, anxiety and depression with no serious cardiac events. This is encouraging, but it was a small study with no placebo arm.

The picture is somewhat better for other psychedelics. MDMA-assisted therapy for PTSD completed Phase 3 trials, though the FDA declined approval in 2024 over concerns about trial design. Psilocybin has received FDA Breakthrough Therapy designation for treatment-resistant depression and multiple large trials are underway.

The Bipartisan Convergence Over Psychedelics

Psychedelic reform has attracted unusual support from both ends of the political spectrum. On the left, advocates frame it as a mental health equity issue and an alternative to opioid treatments. The veterans’ angle is commonly used by the right. An estimated 18 veterans die by suicide each day, and conventional PTSD treatments leave a significant share without meaningful relief. The argument that veterans deserve access to every promising option resonates across party lines.

Texas has been the most aggressive state when it comes to this topic. Governor Abbott signed legislation last year approving $50 million for ibogaine research. Trump’s order directs HHS to channel at least an additional $50 million to states with ibogaine programs, an explicit federal-state partnership designed to encourage other governors to follow.

The issue has also found an unlikely megaphone in Joe Rogan, whose conversations with veterans and ibogaine advocates on his podcast have reached tens of millions of listeners. This has helped build the public pressure that led directly to the executive order, with Rogan present in the Oval Office at the signing.

Oregon and Colorado legalized supervised psilocybin services through ballot initiatives, though federal law remains a barrier.

Trump’s executive order also now directs the FDA and DEA to establish a specific pathway for eligible patients to access investigational psychedelic drugs, including psilocybin and ibogaine, under the Right to Try Act.

The federal Right to Try Act, which was signed into law by Trump in 2018, allows patients with life-threatening conditions to access experimental treatments that have cleared Phase 1 trials. The DEA historically blocked psilocybin access under this pathway due to its Schedule I status.

The FDA next week will also issue national priority vouchers for three psychedelics compressing review timelines from months to weeks. The agency is also clearing the way for the first-ever human ibogaine trials conducted on U.S. soil.

The Expanding Access to Psychedelic Therapy Act was introduced in recent congressional sessions but is not yet passed. The proposed law would explicitly extend that framework to psychedelics, creating a legal pathway for seriously ill patients to access investigational compounds like ibogaine or psilocybin outside of clinical trials.

The Road From Research To Clinical Practice For Psychedelics

Even with renewed federal interest, the path from promising compound to approved therapy is long and uncertain. Full rescheduling requires the DEA to determine, based on FDA’s assessment, that a substance has accepted medical use. The fate of MDMA is the cautionary tale; after clinical trials were completed, the FDA rejected it as an approved therapy. For ibogaine, cardiac safety is the central clinical issue. Any legitimate path to therapeutic use requires robust screening criteria, standardized monitoring and a clear picture of who is eligible.

There is also a question about how ibogaine would be delivered. The Oregon model, where licensed facilitators administering psilocybin in supervised settings, is one way. But it is expensive and labor-intensive. Integrating psychedelic therapies into the VA or community mental health settings would require workforce training, new protocols and a sensible reimbursement model.

Ultimately, Trump’s ibogaine lends federal credibility and resources to a research agenda that has been chronically underfunded because of scheduling decisions made half a century ago. For veterans who have exhausted conventional options, clinical trial enrollment may offer the most realistic near-term path to access.

More broadly, the psychedelic policy shift reflects a growing recognition that the blanket prohibition on researching these substances has denied patients and physicians the information required to safely use a potentially highly effective class of medications. Correcting that requires sustained investment in science, thoughtful regulatory reform and an honest acknowledgment of both the potential benefits and risks.